allAfrica.com on MSN6h
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Zacks.com on MSN20h
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.
IPPMEDIA15h
HIV prevention injection finishes early safety trial
The injection, known as Lenacapavir, works by preventing the virus from multiplying within body cells and could provide protection for an entire year. Researchers noted that the injection differs from ...